# A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Source: https://onco.cc/trials/nct06710847/  
OnCo record `nct06710847` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GSK4418959 in colorectal cancer and endometrial cancer, run by GlaxoSmithKline, active and no longer recruiting.

## Summary

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT06710847 by GlaxoSmithKline, with 14 participants enrolled, started 2024-12-13 and due to reach its primary completion in 2026-06-22. Interventions recorded: GSK4418959 and PD-1 inhibitor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06710847
- Phase: 1/2
- Setting: A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER)
- Sponsor: GlaxoSmithKline
- Enrolled: 14

## Sources

- ClinicalTrials.gov NCT06710847: https://clinicaltrials.gov/study/NCT06710847

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- companies: [GSK](https://onco.cc/companies/gsk/), [IDEAYA Biosciences](https://onco.cc/companies/ideaya-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct06710847.json